RESEARCH PAPER
Effect of eradication of Helicobacter pylori in rheumatoid arthritis patients
| 1 | The Parker Institute, Frederiksberg Hospital, Denmark |
| 2 | Frederiksberg Hospital, Department of Clinical Microbiology, Rigshospitalet, Denmark |
| 3 | Department of Pathology, Denmark |
| 4 | Department of Gastroenterology, Denmark |
| 5 | Department of Microbiology , Denmark |
| 6 | Deceased |
| 7 | The Parker Institute, Frederiksberg Hospital, Denmark; Copenhagen University Library, Section for Science and Medicine, Denmark |
CORRESPONDING AUTHOR
Bente Danneskiold-Samsøe
Parker Instituttet, Frederiksberg Hospital, Nordre Fasanvej 57, 2000 Frederiksberg, Denmark.
Parker Instituttet, Frederiksberg Hospital, Nordre Fasanvej 57, 2000 Frederiksberg, Denmark.
J Pre Clin Clin Res. 2007;1(1):74–79
KEYWORDS
ABSTRACT
Helicobactor pylori (H. pylori) is suspected to be one of the factors triggering rheumatoid arthritis. The aim of this study was to evaluate the effect of H. pylori eradication on inflammatory disease activity in patients with rheumatoid arthritis. The presence of H. pylori was assessed in 59 patients with rheumatoid arthritis from whom H. pylori was eradicated. The level of inflammatory disease activity was evaluated before eradication and during a 42-week follow-up period, as well as the inflammatory disease. The activity of H. pylori in uninfected patients was evaluated with similar time intervals. A significant improvement was seen in the patients’ ESR after H. pylori eradication, although this was non-significant after adjustment for multiple comparisons. A significantly reduced number of tender joints was observed in patients unaffected by H. pylori, possibly due to altered DMARD-treatment in 17% of the patients. Our results indicate the role of H. pylori on the inflammatory state of rheumatoid arthritis, but further studies on larger populations are necessary for final conclusions to be drawn.
REFERENCES (59)
1.
Phillips PE: Infectious agents in the pathogenesis of rheumatoid arthritis. Seminars in Arthr and Rheum 1986, 16, 1-10.
3.
Espinoza LR: Rheumatoid arthritis: Etiopathogenetic considerations. Clin Lab Med 1986, 6 (1), 27-40.
4.
Atkin S, Walker D, Mander M, Malcolm A, Dick WC: Observations on the causes of rheumatoid arthritis. Br J Rheumatol 1988, 27 (Suppl 2), 173-175.
5.
Phillips PE: Evidence implicating infectious agents in rheumatoid arthritis and juvenile rheumatoid arthritis. Clin and Experimental Rheum 1988, 6, 87-94.
6.
Rodriguez MA, Williams RC, Jr.: Infection and rheumatic diseases. Clin Exp Rheumatol 1989, 7(1), 91-97.
7.
Wilder RL, Crofford LJ: Do infectious agents cause rheumatoid arthritis? Clin Orthop 1991, 2(65), 36-41.
8.
Inman RD: Infectious etiology of rheumatoid arthritis. Rheum Dis Clin North Am 1991, 17(4), 859-870.
9.
Burmester GR: Hit and run or permanent hit? Is there evidence for a microbiological cause of rheumatoid arthritis? J Rheumatol 1991, 18(10), 1443-1447.
10.
Ford DK: The microbiological causes of rheumatoid arthritis. J Rheumatol 1991, 18(10), 1441-1442.
11.
Rook GA, Stanford JL: Slow bacterial infections or autoimmunity? Immunol Today 1992, 13(5), 160-164.
12.
Rook GA, Lydyard PM, Stanford JL: A reappraisal of the evidence that rheumatoid arthritis and several other idiopathic diseases are slow bacterial infections. Ann Rheum Dis 1993, 52 (Suppl 1), 30-38.
13.
Gaston JS: The role of infection in inflammatory arthritis. QJM 1994, 87(11), 647-651.
14.
Olhagen B: The intestine and rheumatism. Acta Rheumatol Scand 1970, 16(3), 177-183.
15.
Alspaugh MA, Tan EM: Serum antibody in rheumatoid arthritis reactive with a cell-associated antigen. Arthritis Rheum 1976, 19, 711-719.
16.
Larsen JH: Yersinia enterocolitica infections and rheumatic diseases. Scan J of Rheum 1980, 9, 129-137.
17.
Ferrell PB, Aitcheson CT, Pearson GR, Tan EM: Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis. J Clin Invest 1981, 67(3), 681-687.
18.
Cohen BJ, Buckley MM, Clewly JP, Jones VE, Puttick AH, Jacoby RK: Human parvovirus infection in early rheumatoid and inflammatory arthritis. Ann Rheum Dis 1986, 45, 832-838.
19.
Musiani M, Zerbini M, Ferri S, Plazzi M, Gentilomi G, La Placa M: Comparison of the immune response to Epstein-Barr virus and Cytomegalovirus in sera and synovial fluids of patients with rheumatoid arthritis. Ann Rheum Dis 1987, 46, 837-842.
20.
Clark HW, Coker-Vann MR, Bailey JS, Brown TM: Detection of mycoplasmal antigens in immune complexes from rheumatoid arthritis synovial fluids. Ann Allergy 1988, 60(5), 394-398.
21.
Yokochi T, Yanagawa A, Kimura Y, Mizushima Y: High titer of antibody to the Epstein-Barr virus membrane antigen in sera from patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 1989, 16(8), 1029-1032.
22.
Murayama T, Jisaki F, Ayata M, Sakamuro D, Hironaka T, Hirai K: Cytomegalovirus genomes demonstrated by polymerase chain reaction in synovial fluid from rheumatoid arthritis patients. Clin Exp Rheumatol 1992, 10(2), 161-164.
23.
Saal JG, Steidle M, Einsele H, Muller CA, Fritz P, Zacher J: Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 1992, 12(4), 147-151.
24.
Newkirk MM, Watanabe Duffy KN, Leclerc J, Lambert N, Shiroky JB: Detection of cytomegalovirus, Epstein-Barr virus and herpes virus-6 in patients with rheumatoid arthritis with or without Sjogren's syndrome. Br J Rheumatol 1994, 33(4), 317-322.
25.
Saebo A, Lassen J: Yersinia enterocolitica: An inducer of chronic inflammation. Int J Tissue React 1994, 16(2), 51-57.
26.
Newkirk MM, Duffy KN, Paleckova A, Ivaskova E, Galianova A, Seeman J: Herpes viruses in multicase families with rheumatoid arthritis. J Rheumatol 1995, 22(11), 2055-2061.
27.
Hoffman RW, O'Sullivan FX, Schafermeyer KR, Moore TL, Roussell D, Watson-McKown R: Mycoplasma infection and rheumatoid arthritis: analysis of their relationship using immunoblotting and an ultrasensitive polymerase chain reaction detection method. Arthritis Rheum 1997, 40(7), 1219-1228.
28.
Rider JR, Ollier WE, Lock RJ, Brookes ST, Pamphilon DH: Human cytomegalovirus infection and systemic lupus erythematosus. Clin Exp Rheumatol 1997, 15(4), 405-40.
29.
Schaeverbeke T, Gilroy CB, Bebear C, Dehais J, Taylor-Robinson D: Mycoplasma fermentans, but not M penetrans, detected by PCR assays in synovium from patients with rheumatoid arthritis and other rheumatic disorders. J Clin Pathol 1996, 49(10), 824-828.
30.
Schaeverbeke T, Vernhes JP, Lequen L, Bannwarth B, Bebear C, Dehais J: Mycoplasmas and arthritides. Rev Rheum Engl Ed 1997; 64(2): 120- 128.
31.
Warren JR: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983, 1, 1273.
32.
Marshall BJ: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983, 1, 1273-1275.
33.
Blaser MJ: Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990, 161(4), 626-633.
34.
Andersen LP, Holck S, Povlsen CO, Elsborg L, Justesen T: Campylobacter pyloridis in peptic ulcer disease. I. Gastric and duodenal infection caused by C. pyloridis: histopathologic and microbiologic findings. Scand J Gastroenterol 1987, 22(2), 219-224.
35.
Malone DE, McCormick PA, Daly L, Jones B, Long A, Bresnihan B: Peptic ulcer in rheumatoid arthritis--intrinsic or related to drug therapy? Br J Rheumatol 1986, 25(4), 342-344.
36.
Janssen M, Dijkmans BA, Lamers CB: Upper gastrointestinal manifestations in rheumatoid arthritis patients: Intrinsic or extrinsic pathogenesis ? Scan J Gastroenterol 1990, 25 (Suppl.178), 79-84.
37.
Janssen M, Dijkmans BA, van der Sluys FA: Upper gastrointestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheumatol 1992, 31, 747- 752.
38.
Upadhyay R, Howatson A, McKinlay A, Danesh BJ, Sturrock RD, Russell RI: Campylobacter pylori associated gastritis in patients with rheumatoid arthritis taking nonsteroidal anti-inflammatory drugs. Br J Rheumatol 1988, 27(2), 113-116.
39.
Caselli M, Pazzi P, LaCorte R, Aleotti A, Trevisani L, Stabellini G: Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. Digest 1989, 44(2), 101-104.
40.
Jones ST, Clague RB, Eldridge J, Jones DM: Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis. Br J Rheumatol 1991, 30(1), 16- 20.
41.
Loeb DS, Talley NJ, Ahlquist DA, Carpenter HA, Zinsmeister AR: Longterm nonsteroidal anti-inflammatory drug use and gastroduodenal injury: The role of Helicobacter pylori. Gastroenterol 1992, 102(6), 1899-1905.
42.
Taha AS, Nakshabendi I, Lee FD, Sturrock RD, Russell RI: Chemical gastritis and Helicobacter pylori related gastritis in patients receiving non-steroidal anti-inflammatory drugs: Comparison and correlation with peptic ulceration. J Clin Pathol 1992, 45(2), 135-139.
43.
Taha AS, Sturrock RD, Russell RI: Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1992, 87(12), 1732-1735.
44.
Gubbins GP, Schubert TT, Attanasio F, Lubetsky M, Perez-Perez GI, Blaser MJ: Helicobacter pylori seroprevalence in patients with rheumatoid arthritis: effect of nonsteroidal anti-inflammatory drugs and gold compounds. Am J Med 1992, 93(4), 412-418.
45.
Goggin PM, Collins DA, Jazrawi RP, Jackson PA, Corbishley CM, Bourke BE: Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis. Gut 1993, 34(12), 1677-1680.
46.
Henriksson K, Uribe A, Sandstedt B, Nord CE: Helicobacter pylori infection, ABO blood group, and effect of misoprostol on gastroduodenal mucosa in NSAID-treated patients with rheumatoid arthritis. Dig Dis Sci 1993, 38(9), 1688-1696.
47.
Janssen M, Dijkmans BA, Lamers CB, Zwinderman AH, Vandenbroucke JP: A gastroscopic study of the predictive value of risk factors for nonsteroidal anti-inflammatory drug-associated ulcer disease in rheumatoid arthritis patients. Br J Rheumatol 1994, 33(5), 449-454.
48.
Showji Y, Nozawa R, Sato K, Suzuki H: Seroprevalence of Helicobacter pylori infection in patients with connective tissue diseases. Microbiol Immunol 1996, 40(7), 499-503.
49.
Zentilin P, Savarino V, Garnero A, Accardo S, Seriolo B: Is Helicobacter pylori infection a risk factor for disease severity in rheumatoid arthritis? Gastroenterol 1999, 116(2), 503-504.
50.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31(3), 315-324.
51.
Price AB: The Sydney System: Histological division. J Gastroenterol Hepatol 1991, 6(3), 209-222.
52.
Andersen LP, Espersen F, Souckova A, Sedlackova M, Soucek A: Isolation and preliminary evaluation of a low-molecular-mass antigen preparation for improved detection of Helicobacter pylori immunoglobulin Gantibodies. Clin Diagn Lab Immunol 1995, 2(2), 156-159.
53.
Fries JF, Spitz P, Kraines RG, Holman HR: Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23(2), 137-145.
54.
Fuchs HA, Pincus T: Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum 1994, 37(4), 470-475.
55.
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38(6), 727-735.
56.
Andersen LP, Rosenstock SJ, Bonnevie O, Jorgensen T: Seroprevalence of immunoglobulin G, M, and A antibodies to Helicobacter pylori in an unselected Danish population. Am J Epidemiol 1996, 143(11), 1157- 1164.
57.
Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA: Minocycline in active rheumatoid arthritis. A double-blind, placebocontrolled trial. Arthritis Rheum 1994, 37(5), 629-636.
58.
Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA: Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995, 122(2), 81-89.
59.
Matsuoka N, Eguchi K, Kawakami A, Tsuboi M, Kawabe Y, Aoyagi T: Inhibitory effect of clarithromycin on co-stimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin Exp Immunol 1996, 104(3), 501-508.
RELATED ARTICLE
The Journal of Pre-Clinical and Clinical Research welcomes article
submissions and does not charge a publication fee.
Submit your article today and gain worldwide visibility for your article.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.